Salix Pharmaceuticals, Ltd. today announced the issuance of a patent, entitled "Polymorphous Forms of Rifaximin, Processes for Their Production and Use Thereof in the Medicinal Preparations", by the United States Patent and Trademark Office. This patent, assigned patent number
US 7,045,620, is believed to extend the patent coverage of the current form of
rifaximin, which we market in the United States under the tradename XIFAXAN, until
May 22, 2024.